Johnson & Johnson COVID-19 Booster Shows Significant Increase in Antibody and T-cell Responses Six Months After Two-Dose Regimen with BNT162b2
The Johnson & Johnson booster enhanced neutralising and binding antibodies, similar to boosting with BNT162b2, and demonstrated a high increase in T-cell responses in an initial Phase 2 research and a sub-study, demonstrating the benefit of the mix-and-match method.
On Sunday, Johnson & Johnson released preliminary findings from an independent study led by Dan Barouch, M.D., Ph.D., et al. of Beth Israel Deaconess Medical Center, which found that a booster shot of the Johnson & Johnson COVID-19 vaccine (Ad26.COV2.S), given six months after a two-dose primary regimen of BNT162b2, increased both antibody and T-cell responses. The study included a subset of participants from the Jan These results show the potential advantages of heterologous boosting. The report describing these results is available on medRxiv.
“There is early evidence to suggest that a mix-and-match boosting approach may provide individuals with different immune responses against COVID-19 than a homologous boosting approach. In this preliminary study, when a booster dose of Ad26.COV2.S was given to individuals six months after a primary regimen with the BNT162b2 vaccine, there was a comparable increase of antibody responses at week four following the boost and a greater increase of CD8+ T-cell responses with Ad26.COV2.S compared with BNT162b2.”said Dan Barouch, M.D., Ph.D., Director of the Center for Virology and Vaccine Research at BIDMC.
“These results provide valuable scientific insights for our vaccine when used as a mix-and-match booster and can help inform boosting strategies with the goal to curb the pandemic. These data add to the growing body of evidence demonstrating that a mix-and-match booster dose of the Johnson & Johnson COVID-19 vaccine successfully increases humoral responses and cellular responses against the original strain of SARS-CoV-2, as well as the Beta and Delta variants.”said Mathai Mammen, M.D., Ph.D., Global Head, Janssen Research & Development, Johnson & Johnson.
Initial reports from the UK COV-BOOST clinical research, published in The Lancet, showed that after two doses of either BNT162b2 (n=106) or ChAdOx1 nCov-19 (n=108), a booster dose of the Johnson & Johnson COVID-19 vaccine enhanced both antibody and T-cell responses.